ARTICLE | Clinical News
Lucinactant: Phase IIa data
November 8, 2010 8:00 AM UTC
A double-blind, aerosolized saline-controlled, crossover, U.S. Phase IIa trial in 16 patients with mild to moderate CF showed that five 20 mg doses of aerosolized KL4 surfactant were well tolerated wi...